These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17704253)

  • 21. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
    Costantini DL; Chan C; Cai Z; Vallis KA; Reilly RM
    J Nucl Med; 2007 Aug; 48(8):1357-68. PubMed ID: 17631548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect and mechanism of gefitinib inhibition on non-small cell lung cancer radiosensitivity of HCC827 and H358 cell lines].
    Gao Z; Zhuang L; Chen Y
    Zhongguo Fei Ai Za Zhi; 2012 Jun; 15(6):324-31. PubMed ID: 22681918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Panitumumab-DOTA-
    Facca VJ; Cai Z; Gopal NEK; Reilly RM
    Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 111In- or 99mTc-labeled recombinant VEGF bioconjugates: in vitro evaluation of their cytotoxicity on porcine aortic endothelial cells overexpressing Flt-1 receptors.
    Chan C; Cai Z; Su R; Reilly RM
    Nucl Med Biol; 2010 Feb; 37(2):105-15. PubMed ID: 20152709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
    Reilly RM; Scollard DA; Wang J; Mondal H; Chen P; Henderson LA; Bowen BM; Vallis KA
    J Nucl Med; 2004 Apr; 45(4):701-8. PubMed ID: 15073268
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Cai Z; Chattopadhyay N; Yang K; Kwon YL; Yook S; Pignol JP; Reilly RM
    Nucl Med Biol; 2016 Dec; 43(12):818-826. PubMed ID: 27788375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent.
    Sundberg AL; Orlova A; Bruskin A; Gedda L; Carlsson J; Blomquist E; Lundqvist H; Tolmachev V
    Cancer Biother Radiopharm; 2003 Aug; 18(4):643-54. PubMed ID: 14503960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.
    Huang WC; Chen YJ; Li LY; Wei YL; Hsu SC; Tsai SL; Chiu PC; Huang WP; Wang YN; Chen CH; Chang WC; Chang WC; Chen AJ; Tsai CH; Hung MC
    J Biol Chem; 2011 Jun; 286(23):20558-68. PubMed ID: 21487020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical.
    Cornelissen B; Darbar S; Kersemans V; Allen D; Falzone N; Barbeau J; Smart S; Vallis KA
    Nucl Med Biol; 2012 Nov; 39(8):1142-51. PubMed ID: 22819196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.
    Nishimura Y; Yoshioka K; Bereczky B; Itoh K
    Mol Cancer; 2008 May; 7():42. PubMed ID: 18492291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines.
    Nishimura Y; Bereczky B; Ono M
    Histochem Cell Biol; 2007 May; 127(5):541-53. PubMed ID: 17361439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
    Chan C; Fonge H; Lam K; Reilly RM
    Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of Cell Cytotoxicity and Comet Assay on HER2/neu Positive Cell Line Due to
    Piroozfar B; Alirezapour B; Sedeh FM; Mirzaii M; Jalilian AR; Hashemizadeh M; Raisali G
    Curr Radiopharm; 2022; 15(2):148-156. PubMed ID: 34182918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death.
    Britain CM; Holdbrooks AT; Anderson JC; Willey CD; Bellis SL
    J Ovarian Res; 2018 Feb; 11(1):12. PubMed ID: 29402301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
    Costantini DL; Villani DF; Vallis KA; Reilly RM
    J Nucl Med; 2010 Mar; 51(3):477-83. PubMed ID: 20150272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
    Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
    Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGF-coated gold nanoparticles provide an efficient nano-scale delivery system for the molecular radiotherapy of EGFR-positive cancer.
    Song L; Falzone N; Vallis KA
    Int J Radiat Biol; 2016 Nov; 92(11):716-723. PubMed ID: 26999580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.
    Meco D; Servidei T; Riccardi A; Ferlini C; Cusano G; Zannoni GF; Giangaspero F; Riccardi R
    Neuro Oncol; 2009 Jun; 11(3):250-9. PubMed ID: 19033425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.